Zepbound does not have a price. It has five, and which one a patient meets depends on their insurance status, the physical form of the product, and — this is the part almost nothing published about it explains — whether their last refill arrived on time.
Every figure below was read from Lilly's own Zepbound coverage and savings page on 2026-09-08, including the terms and conditions printed underneath it. This page reports prices and the rules attached to them. It does not say who should take this medicine; that belongs with a prescriber, as our editorial standards set out.
The five prices
| How it is bought | Presentation | Price per month | Condition |
|---|---|---|---|
| Commercial insurance that covers Zepbound | Single-dose Pen | as little as $25 | Card contributes at most $100/month, $1,300/year, 13 fills/year |
| Commercial insurance that does not cover Zepbound | Single-dose Pen | $499 | Maximum saving is wholesale acquisition cost minus $499 |
| Commercial insurance that does not cover Zepbound | KwikPen | $299 / $399 / $449 | By dose; stated maximum monthly savings $215 / $115 / $65 / $271 |
| LillyDirect self-pay | KwikPen or vial | $299 | Quoted at the 2.5 mg starting dose; explicitly not the single-dose Pen |
| Medicare Part D, GLP-1 Bridge | — | no more than $50 | Eligible patients, weight-management prescription, Bridge clinical criteria |
"One month" is not one definition across that table. For the single-dose Pen it is 28 days and up to four pens. For the single-patient-use KwikPen it is 28 days and one KwikPen. Both deliver four weekly doses; the pens differ in how the drug is packaged, not in how much of it a month contains.
The 45-day rule
Here is the finding, and it is in Lilly's own small print rather than anywhere in the consumer coverage of this drug.
The $449 figure that appears in almost every article about what Zepbound costs is not a price. Lilly's page calls it a purchase offer, and the Purchase Offer Terms and Conditions for the single-patient-use KwikPen say what it depends on:
You will automatically receive the $449 purchase offer on your first purchase of the 7.5 mg, 10 mg, 12.5 mg, or 15 mg Zepbound single-patient-use KwikPen. To continue to be eligible for this purchase offer, you must complete your refill purchase of the Zepbound single-patient-use KwikPen within 45 days of the delivery/received date of your previous Zepbound single-patient-use KwikPen prescription fill.
And then, in the same paragraph, what happens when that lapses:
Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg.
So the two numbers that look like a contradiction — $449 here, $699 there — are a schedule and a penalty. A one-month supply is 28 days and one KwikPen. The refill window is 45 days from the previous delivery. That is 17 days of margin on a 28-day supply. Miss it at 10 mg and that month costs $699 instead of $449: a difference of $250 on a single fill.
Nothing about this is hidden — it is published, and Lilly is under no obligation to price a lapsed refill the same as a continuous one. But it changes what the headline number means. The commonly cited "$449 a month for Zepbound" is the price of an uninterrupted course. A patient who travels, whose pharmacy runs short, who pauses over a holiday, or who simply refills at day 50 rather than day 40 is quoted a different number, and the reason will not be on the receipt.
What the savings caps imply
The non-covered KwikPen tier is worth a second look because the numbers resolve neatly:
| Dose | Card price | Stated maximum monthly saving | Sum |
|---|---|---|---|
| 2.5 mg | $299 | $215 | $514 |
| 5 mg | $399 | $115 | $514 |
| 7.5 mg | $449 | $65 | $514 |
| 10 / 12.5 / 15 mg | $449 | $271 | $720 |
The first three lines add to the same figure. That is our arithmetic on Lilly's published caps, not a statement Lilly makes, and the caps are ceilings rather than equalities — but a single reference figure per pen tier is the simplest explanation for why three different doses with three different discounts land on one number. It also means the discount is largest where the underlying price is highest, which is the opposite of how a flat-rate offer would behave.
The $25 that is usually not $25
The second thing worth stating plainly applies to every GLP-1 savings card, and it is arithmetic rather than reporting.
Zepbound's commercial card advertises "as little as $25". Its own terms cap what the card contributes at $100 per one-month prescription. Those two facts together define a ceiling: the card reaches $25 only when the plan's copay is $125 or less. At a $300 copay the card pays $100 and the patient pays $200 — still a real saving, and not $25.
The annual cap confirms the structure. $1,300 per calendar year is exactly 13 × $100, and the card separately allows a maximum of 13 fills per calendar year. The monthly cap, the annual cap and the fill limit are one rule expressed three ways.
This is not specific to Lilly. Novo Nordisk's Wegovy and Ozempic cards use the same $25 headline with the same $100 monthly ceiling, which puts their break-even at the same $125 copay — the difference is that Novo's published footnote states no annual cap, while Lilly's states one. Mounjaro's card, on the same molecule as Zepbound, contributes up to $150 a month, which lifts its ceiling to $175. Our Mounjaro cost page takes that arithmetic further, because Mounjaro's terms publish a number that lets the underlying list price be recovered exactly.
What this costs against what it does
Zepbound is tirzepatide, and the trial that matters for a cost comparison is SURMOUNT-5, the only head-to-head against semaglutide. Its results, the endpoints, and how the two drugs differ mechanically are set out on our tirzepatide vs semaglutide page rather than repeated here.
What belongs on a cost page is the shape of the commitment. These are maintenance medicines: the trial data describes weight regain after discontinuation, so the relevant figure is not one month but a year of months. At the $449 offer price, twelve fills is $5,388. At the $699 regular price, it is $8,388. The gap between those two numbers is the 45-day rule, and it is larger than most of the price differences that get written about.
What we could not establish
Two things, stated because a cost page that only reports what it found is not a cost page.
Lilly's site does not publish a wholesale acquisition cost for Zepbound on the coverage page itself; the non-covered single-dose Pen tier defines its maximum saving as "wholesale acquisition cost minus $499" without printing the cost. The list price commonly quoted for Zepbound, $1,088 per month, comes from a White House statement of 2026-02-05 and is sourced on our GLP-1 cost page.
And Lilly's page shows the $299 LillyDirect self-pay figure against the 2.5 mg dose, which the same page notes is a starting dose and not an approved maintenance dose. What LillyDirect charges for maintenance doses of the vial was not on the page we opened. Anyone reasoning about a year of treatment should treat the $299 as an entry price rather than a running one.
Sources, with dates
- Lilly, Zepbound savings and insurance options, including the savings-card terms and the Purchase Offer Terms and Conditions for the single-patient-use KwikPen — read 2026-09-08. All Zepbound prices, caps, the 45-day refill condition and the Medicare Bridge figure on this page come from it.
- Lilly, Mounjaro savings and coverage — read 2026-09-08, for the Mounjaro card caps quoted in the comparison above.
- Novo Nordisk, Wegovy price guide (document code US26NC00049, April 2026) — read 2026-09-08, for the semaglutide card ceiling quoted above.
Prices in this market changed four times in the twelve months to September 2026. Every figure here carries the date it was read; re-check the manufacturer page before relying on any of them.